US2856415A
(en)
|
1957-11-13 |
1958-10-14 |
Searle & Co |
3,19-dihydroxy-5-androstene derivatives
|
FR1380417A
(fr)
|
1962-05-15 |
1964-12-04 |
Roussel Uclaf |
Nouveaux androstanyl-pyrazoles et procédé de préparation
|
US3206459A
(en)
|
1962-10-19 |
1965-09-14 |
Syntex Corp |
10alpha-pregnan-19-ol derivatives
|
US3169134A
(en)
|
1963-03-21 |
1965-02-09 |
Searle & Co |
2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
|
BE754111A
(fr)
|
1969-07-29 |
1971-01-29 |
Upjohn Co |
Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
|
US3943124A
(en)
|
1970-12-17 |
1976-03-09 |
Gordon Hanley Phillipps |
Chemical compounds
|
GB1380246A
(en)
*
|
1970-12-17 |
1975-01-08 |
Glaxo Lab Ltd |
3alpha-hydroxy-androstanes and esters thereof
|
US3953429A
(en)
*
|
1970-12-17 |
1976-04-27 |
Glaxo Laboratories Limited |
Anaesthetic steroids of the androstance and pregnane series
|
GB1434919A
(en)
|
1972-06-15 |
1976-05-12 |
Glaxo Lab Ltd |
3alpha-hydroxy androstanes
|
GB1430942A
(en)
|
1972-05-05 |
1976-04-07 |
Glaxo Lab Ltd |
21-substituted 3alpha-hydroxy pregnanes
|
US3983111A
(en)
|
1972-05-05 |
1976-09-28 |
Glaxo Laboratories Limited |
Steroidal anaesthetics of the pregnane and 19-norpregnane series
|
GB1436324A
(en)
*
|
1972-05-12 |
1976-05-19 |
Glaxo Lab Ltd |
Anaesthetic 3alpha-hydroxy pregnanes
|
ES432106A1
(es)
|
1973-11-30 |
1976-11-01 |
Schering Ag |
Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
|
US4071625A
(en)
|
1974-05-13 |
1978-01-31 |
Richardson-Merrell Inc. |
19-Oxygenated-5α-androstanes for the enhancement of libido
|
DE2438020A1
(de)
|
1974-08-05 |
1976-02-26 |
Schering Ag |
18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
|
IL48628A0
(en)
|
1974-12-23 |
1976-02-29 |
Schering Ag |
D-homo-20-keto-pregnanes and process for their manufactur
|
DE2526373C2
(de)
|
1975-06-11 |
1983-11-10 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
|
GB1570394A
(en)
|
1976-01-06 |
1980-07-02 |
Glaxo Lab Ltd |
11-acyloxy-3-hydroxy steroids
|
US4192871A
(en)
|
1976-01-06 |
1980-03-11 |
Glaxo Laboratories Limited |
Chemical compounds
|
GB1581234A
(en)
*
|
1976-04-05 |
1980-12-10 |
Glaxo Operations Ltd |
11a - amino - 3a - hydroxysteroids
|
DE2632677A1
(de)
|
1976-07-16 |
1978-01-26 |
Schering Ag |
Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
|
GB1581235A
(en)
|
1977-04-04 |
1980-12-10 |
Glaxo Operations Ltd |
11a-amino-3a-hydroxy-steroids
|
US4389345A
(en)
|
1981-10-09 |
1983-06-21 |
G.D. Searle & Co. |
3-Oxoestra-17-acetonitrile and unsaturated analogs
|
US4495102A
(en)
|
1982-09-03 |
1985-01-22 |
G. D. Searle & Co. |
Aminoalkyl steroids
|
US5319115A
(en)
|
1987-08-25 |
1994-06-07 |
Cocensys Inc. |
Method for making 3α-hydroxy, 3β-substituted-pregnanes
|
US5120723A
(en)
|
1987-08-25 |
1992-06-09 |
University Of Southern California |
Method, compositions, and compounds for modulating brain excitability
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
AU2657292A
(en)
|
1991-09-13 |
1993-04-27 |
Cocensys, Inc. |
Novel gabaa receptor with steroid binding sites
|
DE4232681C2
(de)
|
1992-09-29 |
1994-11-24 |
Sigma Tau Ind Farmaceuti |
17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
|
AU698834B2
(en)
|
1993-05-24 |
1998-11-12 |
Purdue Pharma Ltd. |
Methods and compositions for inducing sleep
|
EP0656365B1
(en)
|
1993-12-02 |
1997-04-09 |
Akzo Nobel N.V. |
Substituted 2beta-morpholinoandrostane derivatives
|
CZ300694A3
(en)
|
1993-12-02 |
1996-05-15 |
Akzo Nobel Nv |
Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
|
US5939545A
(en)
|
1994-02-14 |
1999-08-17 |
Cocensys, Inc. |
Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
|
ES2151593T3
(es)
|
1994-02-14 |
2001-01-01 |
Euro Celtique Sa |
Androstanos y pregnanos para modulacion alosterica del receptor de gaba.
|
AU3125695A
(en)
|
1994-07-21 |
1996-02-22 |
Pharmacia & Upjohn Company |
Neurologically active aminosteroids
|
CZ292881B6
(cs)
|
1994-11-23 |
2003-12-17 |
Euro-Celtique S.A. |
Androstanová a pregnanová řada pro allosterickou modulaci GABA receptoru
|
DE69634039T2
(de)
|
1995-06-06 |
2005-12-08 |
Euro-Celtique S.A. |
Steroidderivate der Androstan- und der Pregnanreihe
|
WO1998005337A1
(en)
*
|
1996-08-01 |
1998-02-12 |
Cocensys, Inc. |
Use of gaba and nmda receptor ligands for the treatment of migraine headache
|
US5994334A
(en)
|
1997-02-05 |
1999-11-30 |
University Of Maryland |
Androgen synthesis inhibitors
|
US5935545A
(en)
|
1997-07-11 |
1999-08-10 |
E. I. Du Pont De Nemours And Company |
Process for producing an aqueous solution comprising ferric chloride
|
ATE307592T1
(de)
*
|
1998-03-11 |
2005-11-15 |
Torbjoern Backstroem |
Epiallopregnanolon zur behandlung von krankheiten des cns
|
HUP0201818A3
(en)
|
1999-04-29 |
2004-04-28 |
Euro Celtique Sa |
3alpha-hydroxy-3beta-methoxymethyl-21-heterocycle substituted steroids with anesthetic activity and pharmaceutical compositions containing the same
|
US7018406B2
(en)
|
1999-11-17 |
2006-03-28 |
Corevalve Sa |
Prosthetic valve for transluminal delivery
|
PT1172371E
(pt)
|
2000-02-18 |
2005-10-31 |
Taiho Pharmaceutical Co Ltd |
Preparacao de derivados esteroides
|
US6855836B2
(en)
|
2000-10-26 |
2005-02-15 |
Jenapharm Gmbh & Co. Kg |
17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
|
JP2004518637A
(ja)
|
2000-11-03 |
2004-06-24 |
ワシントン・ユニバーシティ |
細胞保護活性を有する修飾されたヒドロキシ置換芳香族構造体
|
GR1003861B
(el)
|
2000-12-29 |
2002-04-11 |
|
Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
|
DK1608671T3
(da)
|
2003-03-24 |
2010-05-10 |
Sterix Ltd |
Østrogenderivater som inhibitorer af steroidsulfatase
|
US7781421B2
(en)
|
2003-05-29 |
2010-08-24 |
Washington University |
Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods
|
WO2005051972A1
(en)
|
2003-11-24 |
2005-06-09 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
US20090118248A1
(en)
|
2004-04-23 |
2009-05-07 |
Euro-Celtique S.A. |
3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
|
US8604011B2
(en)
|
2004-09-27 |
2013-12-10 |
The Regents Of The University Of California |
Therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
AU2005330504B2
(en)
|
2004-09-29 |
2010-10-28 |
Harbor Biosciences, Inc. |
Steroid analogs and characterization and treatment methods
|
PT1888080E
(pt)
|
2005-06-09 |
2010-07-06 |
Euro Celtique Sa |
Composiães farmacuticas de um esterëide neuroactivo e as suas utilizaães
|
WO2008063128A1
(en)
*
|
2006-11-21 |
2008-05-29 |
Umecrine Ab |
The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
|
US20090203658A1
(en)
|
2007-01-08 |
2009-08-13 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
DE102007027636A1
(de)
|
2007-06-12 |
2008-12-18 |
Bayer Schering Pharma Aktiengesellschaft |
17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
|
WO2008157460A1
(en)
|
2007-06-15 |
2008-12-24 |
Cook, Kevin, M. |
Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
|
GB0711948D0
(en)
|
2007-06-20 |
2007-08-01 |
Bionature E A Ltd |
Neurosteriod compounds
|
CN101412742B
(zh)
|
2007-10-19 |
2013-07-31 |
天津金耀集团有限公司 |
一种抑制血管新生的硝酸酯药物
|
US20090264443A1
(en)
|
2008-04-18 |
2009-10-22 |
David Helton |
Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
|
CN101624414B
(zh)
|
2008-07-07 |
2013-02-13 |
天津金耀集团有限公司 |
一种抑制血管新生的硝酸酯药物
|
CZ2008434A3
(cs)
|
2008-07-10 |
2009-12-09 |
Ústav organické chemie a biochemie Akademie ved CR, v. v. i. |
Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
|
US20100120733A1
(en)
|
2008-11-07 |
2010-05-13 |
Auspex Pharmaceuticals, Inc. |
Steroid modulators of glucocorticoid receptor
|
WO2011079047A1
(en)
|
2009-12-23 |
2011-06-30 |
Drugtech Corporation |
Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
|
WO2012013816A1
(en)
|
2010-07-30 |
2012-02-02 |
Medexis S.A. |
Compounds and methods for treating neoplasia
|
CN103347525A
(zh)
|
2010-12-15 |
2013-10-09 |
哈博生物科学公司 |
制备3α-氧取代的甾族化合物的方法及化合物
|
CA2828047C
(en)
|
2011-02-15 |
2020-03-10 |
Socpra Sciences Et Genie, S.E.C. |
Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
|
CZ201181A3
(cs)
|
2011-02-15 |
2012-09-12 |
Ústav organické chemie a biochemie Akademie ved CR, v.v.i. |
Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
|
US9388210B2
(en)
|
2011-02-25 |
2016-07-12 |
Washington University |
Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
US9851309B2
(en)
|
2011-03-23 |
2017-12-26 |
Satoshi Watabe |
Ultra-high-sensitive assay of protein and nucleic acid and kit, and novel enzyme substrate
|
JP2014521662A
(ja)
|
2011-07-29 |
2014-08-28 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
GABAA受容体のモジュレーターとしての新規な17β−ヘテロアリール置換ステロイド
|
JP6205362B2
(ja)
|
2011-09-08 |
2017-09-27 |
セージ セラピューティクス, インコーポレイテッド |
神経刺激性のステロイド、組成物、およびそれらの使用
|
ES2738526T3
(es)
|
2011-10-14 |
2020-01-23 |
Sage Therapeutics Inc |
Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
|
BR112014018110B1
(pt)
|
2012-01-23 |
2022-06-07 |
Sage Therapeutics, Inc |
Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
|
WO2013188792A2
(en)
|
2012-06-15 |
2013-12-19 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
SG10201607230SA
(en)
|
2012-06-19 |
2016-10-28 |
Intercept Pharmaceuticals Inc |
Preparation, Uses And Solid Forms Of Obeticholic Acid
|
US20140050789A1
(en)
|
2012-08-13 |
2014-02-20 |
The Regents Of The University Of California |
Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
|
EP2887944B1
(en)
|
2012-08-21 |
2021-10-06 |
Sage Therapeutics, Inc. |
Allopregnanolone for treating refractory status epilepticus
|
WO2014058736A1
(en)
|
2012-10-08 |
2014-04-17 |
Washington University |
Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
EP2916846A4
(en)
*
|
2012-11-09 |
2016-08-10 |
Goodchild Invest Pty Ltd |
NEUROACTIVE STEROIDS AND THEIR USE TO FACILITATE NEUROPROTECTION
|
CA2892811A1
(en)
|
2012-11-30 |
2014-06-05 |
The Regents Of The University Of California |
Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression
|
US9676812B2
(en)
|
2012-12-18 |
2017-06-13 |
Washington University |
Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
|
US8939545B2
(en)
|
2012-12-20 |
2015-01-27 |
Eastman Kodak Company |
Inkjet printing with managed airflow for condensation control
|
CA2831054C
(en)
|
2013-01-09 |
2016-08-30 |
Sapna Life Sciences Corp. |
Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
|
WO2014108808A2
(en)
|
2013-01-09 |
2014-07-17 |
Henry James Lorne |
Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
|
GB201302368D0
(en)
|
2013-02-11 |
2013-03-27 |
Univ Bath |
Compound
|
US9512170B2
(en)
|
2013-03-01 |
2016-12-06 |
Washington University |
Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
|
US9562026B2
(en)
|
2013-03-14 |
2017-02-07 |
Washington University |
Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
|
CN108440633B
(zh)
|
2013-04-17 |
2021-07-13 |
萨奇治疗股份有限公司 |
19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
|
WO2014169836A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids and methods of use thereof
|
WO2014169831A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
|
ES2807264T3
(es)
|
2013-04-17 |
2021-02-22 |
Sage Therapeutics Inc |
Esteroides neuroactivos 19-nor para métodos de tratamiento
|
HUE053900T2
(hu)
|
2013-07-19 |
2021-07-28 |
Sage Therapeutics Inc |
Neuroaktív szteroidok, kompozíciók, és azok alkalmazásai
|
BR112016003862B1
(pt)
|
2013-08-23 |
2022-09-06 |
Sage Therapeutics, Inc |
Compostos esteroides neuroativos, suas composições e seus usos
|
SI3149018T1
(sl)
|
2014-05-29 |
2020-10-30 |
Sage Therapeutics, Inc. |
Nevroaktivni steroidi, sestavki in uporaba le-teh
|
WO2015195962A1
(en)
|
2014-06-18 |
2015-12-23 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
US10172870B2
(en)
|
2014-09-02 |
2019-01-08 |
The Texas A&M University System |
Method of treating organophosphate intoxication by administration of neurosteroids
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
EP3206493B1
(en)
|
2014-10-16 |
2020-05-06 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
SG10202009859YA
(en)
|
2014-10-16 |
2020-11-27 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders
|
ME03749B
(me)
|
2014-11-27 |
2021-04-20 |
Sage Therapeutics Inc |
KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a
|
RS61530B1
(sr)
|
2015-01-26 |
2021-04-29 |
Sage Therapeutics Inc |
Kompozicije i postupci za lečenje poremećaja cns
|
CN105985396A
(zh)
|
2015-02-16 |
2016-10-05 |
苏州泽璟生物制药有限公司 |
氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
|
WO2016134301A2
(en)
|
2015-02-20 |
2016-08-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
WO2016164763A1
(en)
|
2015-04-10 |
2016-10-13 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
MA45276A
(fr)
|
2015-06-18 |
2018-04-25 |
Sage Therapeutics Inc |
Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
|
UY36741A
(es)
|
2015-06-21 |
2016-12-30 |
Prevacus Inc |
Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
|
CA2998134A1
(en)
|
2015-09-08 |
2017-03-16 |
Viewpoint Therapeutics, Inc. |
Compounds and formulations for treating ophthalmic diseases
|
CA3001722A1
(en)
|
2015-10-16 |
2017-04-20 |
Marinus Pharmaceuticals, Inc. |
Injectable neurosteroid formulations containing nanoparticles
|
US20200306262A1
(en)
|
2015-11-20 |
2020-10-01 |
Sage Therapeutics, Inc. |
Compounds and methods of their use
|
EP3426257A4
(en)
|
2016-03-08 |
2019-11-13 |
Sage Therapeutics, Inc. |
NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF
|
US10226550B2
(en)
|
2016-03-11 |
2019-03-12 |
Brigham Young University |
Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
|
US20190233465A1
(en)
|
2016-07-11 |
2019-08-01 |
Sage Therapeutics, Inc. |
C7, c12, and c16 substituted neuroactive steroids and their methods of use
|
DK3481845T3
(da)
|
2016-07-11 |
2023-11-27 |
Sage Therapeutics Inc |
C17, c20 og c21 substituerede neuroaktive steroider og deres anvendelsesmetoder
|
EP3504189A1
(en)
|
2016-08-23 |
2019-07-03 |
Sage Therapeutics, Inc. |
A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
CN108727453A
(zh)
|
2017-04-20 |
2018-11-02 |
华东理工大学 |
新型pd-1抑制剂及其应用
|
WO2019018119A1
(en)
|
2017-07-18 |
2019-01-24 |
Pairnomix, Llc |
METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
|
US11285139B2
(en)
|
2017-08-31 |
2022-03-29 |
Takeda Pharmaceutical Company Limited |
Treatment of CNS conditions
|
JP2020533310A
(ja)
|
2017-09-07 |
2020-11-19 |
セージ セラピューティクス, インコーポレイテッド |
神経刺激性ステロイドおよびそれらの使用方法
|
US20200276209A1
(en)
|
2017-09-11 |
2020-09-03 |
Sage Therapeutics, Inc. |
Methods of treating epilepsy or status epilepticus
|
EP3681510A1
(en)
|
2017-09-14 |
2020-07-22 |
Sage Therapeutics, Inc. |
A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
|
WO2019094724A1
(en)
|
2017-11-10 |
2019-05-16 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treating genetic epileptic disoders
|
KR20200096596A
(ko)
|
2017-12-08 |
2020-08-12 |
세이지 테라퓨틱스, 인크. |
Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
|
EP3728284A1
(en)
|
2017-12-22 |
2020-10-28 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
WO2019126761A1
(en)
|
2017-12-22 |
2019-06-27 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
EP3737687A1
(en)
|
2018-01-12 |
2020-11-18 |
Sage Therapeutics, Inc. |
Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
|
SG11202012344RA
(en)
|
2018-06-12 |
2021-01-28 |
Sage Therapeutics Inc |
A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
|
AR116695A1
(es)
|
2018-10-12 |
2021-06-02 |
Sage Therapeutics Inc |
Los neuroesteroides y sus métodos de uso
|
CA3116892A1
(en)
|
2018-10-19 |
2020-04-23 |
Sage Therapeutics, Inc. |
9(11)-unsaturated neuroactive steroids and their methods of use
|
US20230322846A9
(en)
|
2018-12-05 |
2023-10-12 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
US20220372067A1
(en)
|
2018-12-21 |
2022-11-24 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
|
TW202110824A
(zh)
|
2019-05-24 |
2021-03-16 |
美商賽吉醫療公司 |
化合物、組合物及使用方法
|
JOP20210293A1
(ar)
|
2019-05-31 |
2023-01-30 |
Sage Therapeutics Inc |
ستيرويدات ذات فعالية عصبية وتركيبات منها
|
AU2020304679A1
(en)
|
2019-06-27 |
2022-01-20 |
Sage Therapeutics, Inc. |
Compounds for treating CNS disorders
|
BR112021026462A2
(pt)
|
2019-06-27 |
2022-03-15 |
Sage Therapeutics Inc |
Composições e métodos para tratar distúrbios de cns
|
CN114787174A
(zh)
|
2019-06-27 |
2022-07-22 |
萨奇治疗股份有限公司 |
用于治疗cns病症的组合物和方法
|
US20230018765A1
(en)
|
2019-12-05 |
2023-01-19 |
Sage Therapeutics, Inc. |
A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
|
CA3175324A1
(en)
|
2020-03-18 |
2021-09-23 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
JP2023519241A
(ja)
|
2020-03-25 |
2023-05-10 |
セージ セラピューティクス, インコーポレイテッド |
呼吸器状態の処置のための薬剤の使用
|
WO2021262836A1
(en)
|
2020-06-24 |
2021-12-30 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof
|
KR20230041049A
(ko)
|
2020-07-20 |
2023-03-23 |
세이지 테라퓨틱스, 인크. |
19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법
|
US20240101592A1
(en)
|
2020-11-25 |
2024-03-28 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
AU2022214187A1
(en)
|
2021-01-28 |
2023-07-13 |
Sage Therapeutics, Inc. |
Use of neuroactive steroids for treatment of sexual dysfunction
|
WO2022177718A1
(en)
|
2021-02-18 |
2022-08-25 |
Sage Therapeutics, Inc. |
Use of neuroactive steroid for treatment of sexual dysfunction
|
KR20230158033A
(ko)
|
2021-03-17 |
2023-11-17 |
세이지 테라퓨틱스, 인크. |
주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
|
WO2022221195A1
(en)
|
2021-04-12 |
2022-10-20 |
Sage Therapeutics, Inc. |
Treatment of essential tremor
|
JP2024515830A
(ja)
|
2021-04-29 |
2024-04-10 |
セージ セラピューティクス, インコーポレイテッド |
母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド
|
MX2023012727A
(es)
|
2021-04-29 |
2023-11-08 |
Sage Therapeutics Inc |
Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.
|